Skip to main content

Revvity United Kingdom revenue

  • RVTY · NYSE
  • Instruments
  • Health Care Equipment
  • S&P 500
$154.39−1.67%Close 13 Nov 2026 · Market value $16.71B

United Kingdom revenue at Revvity came to $126.8M for the fiscal year to 28 Dec 2025, up 12.4% from a year earlier.

As Revvity reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 24 Feb 2026.

By fiscal year

$81.1MDec 2014$69.1MJan 2016$65.9MJan 2017$65.2MDec 2017$72.1MDec 2018$70.7MDec 2019$323.8MJan 2021$357.9MJan 2022$136.0MJan 2023$125.4MDec 2023$112.9MDec 2024$126.8MDec 2025
Revvity United Kingdom revenue, every reported period
Period endingUnited Kingdom revenueChange on a yearFiled
28 Dec 2025$126.8Mup 12.4%24 Feb 2026
29 Dec 2024$112.9Mdown 10.0%25 Feb 2025
31 Dec 2023$125.4Mdown 7.8%27 Feb 2024
1 Jan 2023$136.0Mdown 62.0%1 Mar 2023
2 Jan 2022$357.9Mup 10.5%3 Mar 2022
3 Jan 2021$323.8Mup 358.0%2 Mar 2021
29 Dec 2019$70.7Mdown 2.0%25 Feb 2020
30 Dec 2018$72.1Mup 10.7%26 Feb 2019
31 Dec 2017$65.2Mdown 1.1%27 Feb 2018
1 Jan 2017$65.9Mdown 4.6%28 Feb 2017
3 Jan 2016$69.1Mdown 14.8%1 Mar 2016
28 Dec 2014$81.1Mdown 39.3%24 Feb 2015
29 Dec 2013$133.6Mup 12.6%25 Feb 2014
30 Dec 2012$118.6Mup 15.9%26 Feb 2013
1 Jan 2012$102.4Mup 5.3%28 Feb 2012
2 Jan 2011$97.2Mdown 6.9%1 Mar 2011
3 Jan 2010$104.4M—1 Mar 2010

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of Revvity: Reconciliati on of financial organic revenue growth from continuing operations (change on a year) · Product revenue · Service revenue · Life Sciences revenue · Diagnostics revenue · United States revenue · China revenue · Americas revenue · Europe revenue · Germany revenue · Asia revenue · financial statements

Every KPI and segment of RVTY, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.